The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped ...

Biocon is gearing up to become a dominant player in the diabetes and obesity drug market. This comes as the pharma world ...

For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Novo Nordisk's semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting Competition in the mainland Chinese market for diabetes and weight loss drugs is set to ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

With IRS tax refunds set to arrive, averaging around $3,000, many Americans are weighing the best ways to use the extra cash.